Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the first quarter ended March 31, 2023. The Company also posted its first quarter Letter to Stockholders and corporate presentation to…
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today reported financial results for…
Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of preclinical data that describe the application of the company’s IMPACT platform at PEGS Boston 2023, taking place on…
Today announced that it has executed an agreement with Australia’s national science agency, CSIRO, for full ownership of a polymer technology patent family. Foldax has incorporated the polymer technology into…
Worldwide Clinical Trials (Worldwide), the industry’s leading global, full-service contract research organization (CRO), has partnered with Every Cure, a nonprofit organization that unlocks new, often undiscovered uses for existing approved drugs by…
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates and financial results for the first quarter…
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended…
Forge Biologics, a leading manufacturer of genetic medicines, announced today that eight presentations, including four oral presentations, will be delivered during the upcoming 26th Annual Meeting of the American Society of…
Angelini Pharma, part of the privately owned Angelini Industries, and JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) announced today that they entered into an exclusive global development and commercialization agreement for the…
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective and efficient manufacture of cell and gene therapies (CGTs), has today announced a collaborative partnership with ScaleReady, a joint venture…
Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended March…
Extend Biosciences (“ExtendBio”), a clinical stage biopharmaceutical company utilizing a proprietary platform technology to develop advanced therapeutic peptides, today announced positive results from its first-in-human trial of EXT608. An interim…